Literature DB >> 7934431

Is chest pain after sumatriptan oesophageal in origin?

L A Houghton1, J M Foster, P J Whorwell, J Morris, P Fowler.   

Abstract

3-5% of patients taking the 5HT1D agonist sumatriptan for migraine have chest discomfort, suggesting a cardiac origin. We have investigated an alternative explanation of an oesophageal cause in 24 volunteers after the subcutaneous administration of a supratherapeutic dose of sumatriptan (16 mg) or placebo in a randomised, double-blind crossover study. Sumatriptan did not alter the electrocardiogram but increased the amplitude (p < 0.001) and duration (p < 0.001) of oesophageal contractions without affecting velocity of propagation. Clinically abnormal motility was also increased (p = 0.001), and was more common in the 5 subjects with chest pain after sumatriptan. The effect of sumatriptan on oesophageal function provides an alternative explanation for the chest symptoms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7934431     DOI: 10.1016/s0140-6736(94)91642-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

Review 1.  Almotriptan: a review of its use in migraine.

Authors:  Susan J Keam; Karen L Goa; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Marked sexual dimorphism in 5-HT1 receptors mediating pronociceptive effects of sumatriptan.

Authors:  Dioneia Araldi; Luiz F Ferrari; Paul Green; Jon D Levine
Journal:  Neuroscience       Date:  2016-12-29       Impact factor: 3.590

3.  Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane.

Authors:  A Maassen VanDenBrink; W A Bax; M D Ferrari; F J Zijlstra; E Bos; P R Saxena
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

4.  Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery.

Authors:  J Longmore; J J Maguire; A MacLeod; L Street; W N Schofield; R G Hill
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 5.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 6.  Sumatriptan. An updated review of its use in migraine.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.